Scynexis (SCYX) Preferred Stock Liabilities (2013 - 2014)

Scynexis' (SCYX) quarterly Preferred Stock Liabilities came in at $4.2 million in Q1 2014, down 82.52% on a QoQ basis from $24.1 million in Q4 2013.

Scynexis (SCYX) Preferred Stock Liabilities (2013 - 2014) Analysis & Trends

Scynexis (SCYX) has 2 years of Preferred Stock Liabilities data on file, last reported at $4.2 million in Q1 2014.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $4.2 million in Q1 2014, while the trailing twelve-month figure through Mar 2014 was $4.2 million (changed N/A YoY) and the FY2013 annual result came in at $24.1 million, changed N/A from the prior year.
Preferred Stock Liabilities retreated to $4.2 million in Q1 2014, from $24.1 million in the prior quarter.
In the past five years, Preferred Stock Liabilities ranged from a high of $24.1 million in Q4 2013 to a low of $4.2 million in Q1 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn	-
3	Zoetis	31.78 Bn	30.11 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.71 Bn	22.91 Bn	5.10 Bn	-
5	United Therapeutics	22.25 Bn	19.59 Bn	683.80 Mn	-
6	Viatris	18.72 Bn	17.83 Bn	1.46 Bn	-
7	Neurocrine Biosciences	15.57 Bn	15.18 Bn	935.80 Mn	-
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.14 Bn	9.97 Bn	-	-
10	Scynexis	61.90 Mn	-52.80 Mn	-	-

Download Data

Date	Value
Mar 31, 2014	4.22 Mn
Dec 31, 2013	24.12 Mn